Relates to prohibiting supervised injection sites; provides that it shall be unlawful for any person to own, operate, work in or volunteer at a supervised injection site; defines terms and establishes penalties.
A09126 would amend the Public Health Law and Education Law to prohibit supervised injection sites in New York. The bill defines a “supervised injection site” as a facility where individuals may possess or use controlled substances, or where a practitioner may dispense or administer controlled substances, while being supervised by trained medical personnel. It expressly excludes opioid treatment programs and certain addiction, chemical dependence, and behavioral health programs that are certified, licensed, funded, or operated by the Office of Addiction Services and Supports.
The bill makes it unlawful for any person to own, operate, work in, or volunteer at a supervised injection site. It also adds ownership or operation of such a site as a basis for professional discipline under the Public Health Law and Education Law, including a new professional misconduct provision for licensed professionals who violate the prohibition. The act would take effect immediately.
Its practical impact would be to bar overdose-prevention or supervised consumption facilities from operating in New York and to expose participants and operators to legal and professional penalties. It would also amend existing controlled-substance and professional conduct statutes to treat supervised injection sites as prohibited activity, while preserving the status of existing opioid treatment and state-regulated addiction services programs.
The available legislative history suggests the bill has support in committee, but not unanimous support: the Assembly Health Committee vote was 17-6 to hold the bill for consideration. That indicates the measure has generated interest and some backing, but also meaningful opposition or concern, likely reflecting broader debate over harm-reduction strategies versus enforcement-based approaches to drug use.
The main point of contention is whether supervised injection sites reduce overdose deaths and connect people to treatment, or instead normalize illegal drug use and conflict with state policy. Supporters of the prohibition are likely focused on preventing facilities that allow controlled-substance use, while opponents are likely concerned that banning such sites could limit public-health tools aimed at reducing overdose risk and engaging people with addiction services.
The bill would add a new statutory definition of “supervised injection site” to the Public Health Law, create a new section making such sites unlawful, and amend controlled-substance and professional discipline provisions to penalize ownership or operation of these sites. It would also add a corresponding professional misconduct ground in the Education Law for licensed professionals who violate the prohibition. The measure would not affect opioid treatment programs or certain certified, licensed, funded, or operated addiction and behavioral health programs under OASAS.
The bill appears to have a mixed but somewhat favorable reception in committee, with the Assembly Health Committee voting 17-6 to hold it for consideration. That vote suggests there is enough support to keep the proposal moving, but also substantial concern or disagreement. No transcript was provided, so the broader discussion can only be inferred from the bill’s subject matter and the committee vote.
The central controversy is over supervised injection sites as a harm-reduction strategy. Supporters of the bill likely view these facilities as incompatible with drug-control policy and public safety, and want to prevent any person from operating or staffing them. Opponents are likely to argue that such sites can prevent overdose deaths, reduce public drug use, and connect people to treatment, and that a blanket prohibition could undermine public-health responses to the opioid crisis. The carve-outs for opioid treatment programs and OASAS-regulated services suggest some effort to distinguish supervised injection sites from existing treatment infrastructure.